Back

PREFER­HF: Effects intravenous iron or oral iron therapy compared to placebo in HFpEF with iron deficiency anemia

18 May 2025 (12:03 - 12:11)
Organised by: Logo
Congress Presentation Part of: Hottest trials and trial updates (2) Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Jose Luis Morales Rull

University Hospital Arnau de Vilanova, Lleida (Spain)

20 More presentations in this session

Presentation thumbnail
DIGIT­HF: Baseline characteristics compared to recent trials in heart failure with reduced ejection fraction
Professor U. Bavendiek (Hannover, DE)
Slides Video
Presentation thumbnail
Discussant review - DIGIT­HF
Professor D. van Veldhuisen (Groningen, NL)
Slides Video
Presentation thumbnail
Panel discussion - DIGIT­HF
Video
Presentation thumbnail
CIRRUS­HCM: A multiple-dose phase 2 study of safety, tolerability, and effects on hemodynamics and functional capacity of the novel cardiac sarcomere modulator EDG-7500 in hypertrophic cardiomyopathy
Doctor A. Owens (Philadelphia, US)
Slides Video
Presentation thumbnail
Discussant review - CIRRUS­HCM
Professor I. Olivotto (Florence, IT)
Slides Video

Access the full session

Session thumbnail
Hottest trials and trial updates (2)
Video

The Event

Event poster

Heart Failure 2025

18 May 2025 12:03 CET
You may be interested in
thumbnail
Congress Presentation
Effects of intravenous IRON supplementation in Heart Failure with Preserved Ejection Fraction (IRON-HFpEF): a comprehensive multicenter phase 2 randomized clinical trial
thumbnail
Congress Presentation
Discussant review - PREFER­HF
thumbnail
Congress Presentation
Effect of IV iron in patients with heart failure with preserved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources